Mannkind Corp (MNKD) Stock Price, Quote & News

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provi...

Industry: Biotechnology

Sector: Healthcare

Phone: 818 661 5000

Website: mannkindcorp.com

Address:

1 Casper Street, Danbury, United States

grampslol Apr. 18 at 5:59 PM

$MNKD #afizzle

0 · Reply

firefox2778 Apr. 18 at 4:03 PM

$MNKD oh look Lqda down almost 6% while this one up almost 5%. How is that nobody points to obvious when things play in Mnkd favor? Of course LQDA is killing it, but hey don’t be those guy just happy when we are down and them up.

0 · Reply

clan Apr. 18 at 3:44 PM

$MNKD $JNJ $PFE 👽 🚫💉 Release the files! #inhalemyinsulin #afrezza #morkfromork

0 · Reply

grampslol Apr. 18 at 3:33 PM

$MNKD the answer is no...

1 · Reply

BigCheeze2014 Apr. 18 at 12:50 PM

$MNKD Has Castagna ever acknowledged the pathetic script # and PPS?

3 · Reply

clan Apr. 18 at 12:22 PM

$MNKD Who would doubt that now in India, Afrezza is helping babies and puppies with pediatric👶 and canine🐕 diabetes?!?

1 · Reply

grampslol Apr. 18 at 10:49 AM

$MNKD home to Afizzle DPI #blackboxlabel #coughcough

0 · Reply

grampslol Apr. 18 at 10:44 AM

Poor $MNKD pumper clan... smh... deluding himself as he tries to deceive the naive...sad #epicflop #pennyland #buynowcrylater #pumperslie

0 · Reply

clan Apr. 18 at 9:04 AM

$MNKD More, and bigger, green to come. The reason for the season. Earnings soon. PDUFA soon. Trial results soon. Conference exhibits soon. Record quarterly Revenues ... now. #loadup #buylow

0 · Reply

redbugs Apr. 18 at 8:29 AM

$MNKD Mnkd sold off 1 percent of their uthr royalties for cash. If uthr severs its relationship with mnkd what is the legal consequences? Must mnkd refund monies..pay a penalty..or both?

1 · Reply

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Mar 5, 2026, 4:30 PM EST - 6 weeks ago

MannKind Announces Settlement of Convertible Senior Notes

Mar 4, 2026, 9:00 AM EST - 6 weeks ago

MannKind to Participate in Upcoming Investor Conferences

Feb 26, 2026, 8:00 AM EST - 7 weeks ago

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 19, 2026, 9:00 AM EST - 2 months ago

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 9:00 AM EST - 2 months ago

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 9, 2026, 6:05 AM EST - 2 months ago

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

Jan 26, 2026, 6:05 AM EST - 2 months ago

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

Jan 12, 2026, 3:57 PM EST - 3 months ago

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

AAPL DT GLD ITRN NVDA OMC UTHR

Jan 8, 2026, 8:05 AM EST - 3 months ago

MannKind Provides Business Updates and 2026 Growth Drivers

Dec 23, 2025, 8:05 AM EST - 4 months ago

MannKind Shares FUROSCIX® Business Updates

Dec 1, 2025, 8:05 AM EST - 4 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

Nov 11, 2025, 4:05 PM EST - 5 months ago

MannKind to Present at the Jefferies Global Healthcare Conference

Nov 10, 2025, 8:00 AM EST - 5 months ago

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

Nov 6, 2025, 9:00 AM EST - 5 months ago

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

Nov 5, 2025, 8:00 AM EST - 5 months ago

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 4:05 PM EDT - 6 months ago

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

Oct 13, 2025, 8:05 AM EDT - 6 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

Oct 7, 2025, 9:02 AM EDT - 6 months ago

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Sep 29, 2025, 6:05 AM EDT - 7 months ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

Sep 16, 2025, 12:17 PM EDT - 7 months ago

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SCPH

Aug 27, 2025, 4:05 PM EDT - 8 months ago

MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 8:05 AM EDT - 8 months ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Aug 25, 2025, 1:57 PM EDT - 8 months ago

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

Aug 6, 2025, 7:10 AM EDT - 9 months ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:05 AM EDT - 9 months ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Jul 30, 2025, 4:05 PM EDT - 9 months ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jun 11, 2025, 7:01 AM EDT - 11 months ago

Top 3 Health Care Stocks That May Rocket Higher This Quarter

Jun 9, 2025, 4:05 PM EDT - 11 months ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

May 27, 2025, 9:15 AM EDT - 11 months ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 8, 2025, 8:05 AM EDT - 1 year ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 1 year ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Apr 7, 2025, 12:30 PM EDT - 1 year ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Mar 10, 2025, 6:05 AM EDT - 1 year ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Feb 26, 2025, 4:05 PM EST - 1 year ago

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 4:05 PM EST - 1 year ago

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Jan 6, 2025, 4:30 PM EST - 1 year ago

MannKind Expands Executive Leadership Team

Dec 16, 2024, 6:05 AM EST - 1 year ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Dec 11, 2024, 6:00 AM EST - 1 year ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

Nov 7, 2024, 4:02 PM EST - 1 year ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Nov 5, 2024, 4:15 PM EST - 1 year ago

MannKind to Present at 2024 UBS Healthcare Conference

Nov 4, 2024, 6:05 AM EST - 1 year ago

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

Oct 31, 2024, 4:05 PM EDT - 1 year ago

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

Oct 30, 2024, 9:00 PM EDT - 1 year ago

First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Sep 30, 2024, 6:00 AM EDT - 1 year ago

More Adults With Type 1 Diabetes Achieved A1C Goal (

Sep 18, 2024, 6:15 AM EDT - 1 year ago

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Sep 10, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 27, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at Upcoming Conferences

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board

Aug 7, 2024, 8:00 AM EDT - 1 year ago

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

grampslol Apr. 18 at 5:59 PM

$MNKD #afizzle

0 · Reply

firefox2778 Apr. 18 at 4:03 PM

0 · Reply

clan Apr. 18 at 3:44 PM

$MNKD $JNJ $PFE 👽 🚫💉 Release the files! #inhalemyinsulin #afrezza #morkfromork

0 · Reply

grampslol Apr. 18 at 3:33 PM

$MNKD the answer is no...

1 · Reply

BigCheeze2014 Apr. 18 at 12:50 PM

$MNKD Has Castagna ever acknowledged the pathetic script # and PPS?

3 · Reply

clan Apr. 18 at 12:22 PM

$MNKD Who would doubt that now in India, Afrezza is helping babies and puppies with pediatric👶 and canine🐕 diabetes?!?

1 · Reply

grampslol Apr. 18 at 10:49 AM

$MNKD home to Afizzle DPI #blackboxlabel #coughcough

0 · Reply

grampslol Apr. 18 at 10:44 AM

Poor $MNKD pumper clan... smh... deluding himself as he tries to deceive the naive...sad #epicflop #pennyland #buynowcrylater #pumperslie

0 · Reply

clan Apr. 18 at 9:04 AM

$MNKD More, and bigger, green to come. The reason for the season. Earnings soon. PDUFA soon. Trial results soon. Conference exhibits soon. Record quarterly Revenues ... now. #loadup #buylow

0 · Reply

redbugs Apr. 18 at 8:29 AM

$MNKD Mnkd sold off 1 percent of their uthr royalties for cash. If uthr severs its relationship with mnkd what is the legal consequences? Must mnkd refund monies..pay a penalty..or both?

1 · Reply

clan Apr. 18 at 8:21 AM

$MNKD Nintedanib DPI - coming soon to a pharmacy near you! For the good of all Mannkind and mankind! $MRK $AMGN

0 · Reply

Kuka Apr. 18 at 3:15 AM

$MNKD there must be some Indian Americans on this board. It would be nice if they could call back home and ask someone to check with the pharmacies to see if Afrezza is selling...

0 · Reply

kevinmik Apr. 18 at 1:01 AM

$MNKD United Therapeutic posted a new job opening today for DPI manufacturing position. https://vhr-unither.wd5.myworkdayjobs.com/en-US/External/details/Pharmaceutical-Manufacturing-Technician-II--DPI-_R04939 Jump to selected job details Pharmaceutical Manufacturing Technician II (DPI) locations RTP, NC posted on Posted Today R04939

2 · Reply

grampslol Apr. 18 at 12:00 AM

$MNKD Pennyland

1 · Reply

CaliberPalaceTrades Apr. 17 at 11:47 PM

Crazy call, Made me super green this week, Thank you so much 🔥 If you prefer to buy them runners early instead of chasing, I would start Following that @ElevenXProfits Crazy bull 💯🤑 Should see insane runs on $BULL $IOVA $RCAT $MNKD soon

1 · Reply

clan Apr. 17 at 11:17 PM

$MNKD Q: Mannkind 2026 Revenue forecast? A: >$500,000,000.00 [$1/2 BILLION] #markthispost

0 · Reply

Outcomes Apr. 17 at 10:07 PM

$MNKD

1 · Reply

whiskyqueen Apr. 17 at 9:40 PM

$MNKD Added a few thousand cheapies near the close. Under $3 is kind of still a no brainer here..

0 · Reply

DorianMD Apr. 17 at 9:39 PM

$MNKD I hope this can touch $4..

1 · Reply

clan Apr. 17 at 9:33 PM

$MNKD $DXCM For the best time-in-range [TIR]! Afrezza + G7 Mannkind + Dexcom 👀$LLY 👀

1 · Reply

Big_N_Long Apr. 17 at 9:18 PM

$MNKD I am a Buyer under $10.00 / share. Just researched MNKD’s stock predictions for the next 12 months. The majority of the experts say MNKD is a “Strong Buy”. I agree and predict this stock is about to take off which is why I am buying more shares. I really would like to purchase a new higher flying jet with more speed and longer range and I believe this stock may make my dream come true. This stock may jump 4Xs its current value. If this stock hits my number I will likely sell some shares. I am a proud supporter of the Mannkind company that has good people endeavoring to provide great medical products for those in need. I enjoy investing in great companies with products the help others. Let’s go Longs!

3 · Reply

kevinmik Apr. 17 at 9:12 PM

$MNKD Mannkind MNKD-201 Phase 1B Study was updated yesterday 4/16/2026, to include IPDSharing. Information sharing ! https://clinicaltrials.gov/study/NCT07344558?term=mannkind&viewType=Card&aggFilters=status:rec&rank=1&tab=history A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis ClinicalTrials.gov ID NCT07344558 Sponsor Mannkind Corporation Information provided by Mannkind Corporation (Responsible Party) Last Update Posted 2026-04-16

1 · Reply

Market Cap	849.19M
Revenue (ttm)	348.97M
Net Income (ttm)	5.86M
EPS (ttm)	N/A
PE Ratio	138.50
Forward PE	N/A
Profit Margin	1.68%
Debt to Equity Ratio	-8.78

Volume	3,549,700
Avg Vol	6,051,066
Day's Range	N/A - N/A
Shares Out	308.80M
Stochastic %K	99%
Beta	1.04
Analysts	Strong Sell
Price Target	$7.17